<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> represents the fourth commonest <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, and constitutes a major cause of significant morbidity and mortality among other diseases </plain></SENT>
<SENT sid="1" pm="."><plain>However, the chemical therapy is still under development </plain></SENT>
<SENT sid="2" pm="."><plain><z:mpath ids='MPATH_177'>Angiogenesis</z:mpath> plays an important role in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> development </plain></SENT>
<SENT sid="3" pm="."><plain>We developed HMQ18-22 (a novel analog of taspine) with the aim to target <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>We found that HMQ18-22 significantly <z:mp ids='MP_0005602'>reduced angiogenesis</z:mp> of chicken chorioallantoic membrane (CAM) and mouse colon tissue, and inhibited cell migration and tube formation as well </plain></SENT>
<SENT sid="5" pm="."><plain>Then, we verified the interaction between HMQ18-22 and VEGFR2 by AlphaScreen P-VEGFR assay, screened the targets on <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> by VEGF Phospho Antibody Array, validated the target by western blot and RNAi in lovo cells </plain></SENT>
<SENT sid="6" pm="."><plain>We found HMQ18-22 could decrease phosphorylation of VEGFR2(Tyr(1214)), VEGFR1(Tyr(1333)), Akt(Tyr(326)), protein kinase Cα (PKCα) (Tyr(657)) and phospholipase-Cγ-1 (PLCγ-1) (Tyr(771)) </plain></SENT>
<SENT sid="7" pm="."><plain>Most importantly, HMQ18-22 inhibited proliferation of lovo cell and <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in a human <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colon tumor</z:e> xenografted model of athymic mice </plain></SENT>
<SENT sid="8" pm="."><plain>Compared with <z:mpath ids='MPATH_458'>normal</z:mpath> lovo cells proliferation, the inhibition on proliferation of knockdown cells (VEGFR2, VEGFR1, Akt, PKCα and PLCγ-1) by HMQ18-22 decreased </plain></SENT>
<SENT sid="9" pm="."><plain>These results suggested that HMQ18-22 is a novel <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> inhibitor and can be a useful therapeutic candidate for <z:hpo ids='HP_0003003'>colon cancer</z:hpo> intervention </plain></SENT>
</text></document>